Title: Clinical features of inflammatory bowel disease unclassified: a case-control study
Version: 1 Date: 30 Sep 2023
Reviewer's report:
Dear Author,
I read with interest this paper about the clinical features of inflammatory bowel disease
unclassified; the manuscript is well written, but I want to share some considerations:
-The paper doesn’t include patients affected by IBD and in therapy with other biologics except
anti-TNF#: I don’t understand why you didn’t include other therapies, in particular in the era
of the concept of ‘’target therapy’’.
In line 176-179, you say: ‘’The IBDU group had a higher prevalence of upper gastrointestinal
involvement (8.1% vs 0.0%, P<0.05), ileal involvement (21.6% vs 9.5%, P<0.05)and rectal
sparing (59.5% vs 2.7%, P<0.01), compared with the UC group.’’ This is not relevant, since UC
has not an upper GI localization.’’
I’m sorry, but I suggest to reject the work.
Title: Clinical features of inflammatory bowel disease unclassified: a case-control study
Version: 1 Date: 30 Sep 2023
Reviewer's report:
Dear Author,
I read with interest this paper about the clinical features of inflammatory bowel disease
unclassified; the manuscript is well written, but I want to share some considerations:
-The paper doesn’t include patients affected by IBD and in therapy with other biologics except
anti-TNF#: I don’t understand why you didn’t include other therapies, in particular in the era
of the concept of ‘’target therapy’’.
In line 176-179, you say: ‘’The IBDU group had a higher prevalence of upper gastrointestinal
involvement (8.1% vs 0.0%, P<0.05), ileal involvement (21.6% vs 9.5%, P<0.05)and rectal
sparing (59.5% vs 2.7%, P<0.01), compared with the UC group.’’ This is not relevant, since UC
has not an upper GI localization.’’
I’m sorry, but I suggest to reject the work.
Please review this paper.
user
Title: Clinical features of inflammatory bowel disease unclassified: a case-control study
Version: 1 Date: 30 Sep 2023
Reviewer's report:
Dear Author,
I read with interest this paper about the clinical features of inflammatory bowel disease
unclassified; the manuscript is well written, but I want to share some considerations:
-The paper doesn’t include patients affected by IBD and in therapy with other biologics except
anti-TNF#: I don’t understand why you didn’t include other therapies, in particular in the era
of the concept of ‘’target therapy’’.
In line 176-179, you say: ‘’The IBDU group had a higher prevalence of upper gastrointestinal
involvement (8.1% vs 0.0%, P<0.05), ileal involvement (21.6% vs 9.5%, P<0.05)and rectal
sparing (59.5% vs 2.7%, P<0.01), compared with the UC group.’’ This is not relevant, since UC
has not an upper GI localization.’’
I’m sorry, but I suggest to reject the work.
assistant